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This  randomized,  double-blind  study  evaluated  concomitant  administration  of 13-valent  pneumococcal
conjugate  vaccine  (PCV13)  and trivalent  inactivated  inﬂuenza  vaccine  (TIV)  in adults  aged  ≥65 years  who
were  naïve  to 23-valent  pneumococcal  polysaccharide  vaccine.  Patients  (N = 1160)  were  randomized  1:1
to  receive  PCV13  + TIV followed  by  placebo,  or Placebo  +  TIV followed  by PCV13  at 0  and  1  months,  withvailable online 25 May 2011
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blood  draws  at 0, 1, and 2 months.  Slightly  lower  pneumococcal  serotype-speciﬁc  anticapsular  polysac-
charide  immunoglobulin  G geometric  mean  concentrations  were  observed  with  PCV13 + TIV  relative  to
PCV13.  Concomitant  PCV13  +  TIV  demonstrates  acceptable  immunogenicity  and  safety  compared  with
either  agent  given  alone.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.afety
. Introduction
Diseases caused by Streptococcus pneumoniae are a major health
roblem. The World Health Organization has estimated that 1.6
illion people die annually from pneumococcal disease. For indi-
iduals aged ≥65 years, the reported worldwide incidence of
nvasive pneumococcal disease (IPD) ranges from 24 to 85 per
00,000 persons [1]. As the treatment of pneumococcal disease is
imited by the continuous increase in antimicrobial resistance of
. pneumoniae, vaccination is considered an important preventive
trategy [1,2].
Currently, a 23-valent pneumococcal polysaccharide vaccine
PPV) is available for the protection of older persons against
neumococcal disease. PPV has the drawbacks of poorly deﬁned
accine efﬁcacy, lack of priming, risk of hyporesponsiveness, and
 decline of antibodies over 5 years at different rates for the
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Open access under CC BY-NC-ND license.23 serotypes [1–4]. A 7-valent pneumococcal conjugate vaccine
(PCV7; Prevnar®/Prevenar®; Pﬁzer Inc) is available for infants and
children. Since PCV7’s licensure in 2000 in the USA, the incidence
of IPD caused by vaccine serotypes has decreased not only in those
aged <2 years, but also among adults because of the indirect effects
of herd immunity [5]. Nevertheless, IPD death rates in adults aged
>50 years still remain 11- to 28-fold higher than in children aged
1 year [6]. Additionally, adults with certain comorbid conditions
may beneﬁt less than healthier adults from the indirect effects of
the pneumococcal conjugate vaccine [7].
Pﬁzer is developing a 13-valent pneumococcal conjugate vac-
cine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,
and 23F) for adults and children to prevent pneumococcal disease
caused by the vaccine serotypes. PCV13 has been approved for use
in infants and young children in the United States, Europe, and
other countries. Like PCV7, PCV13 is manufactured using glycocon-
jugate technology. By conjugating the puriﬁed capsular saccharides
of S. pneumoniae to an immunogenic protein carrier, the normally
T-cell-independent response elicited by free polysaccharides is
converted to a T-cell-dependent immune response. In children,
PCV7 induces immunologic memory and boosts antibody responses
upon repeated vaccination, overcoming the limitations of the
5 ccine 29 (2011) 5195– 5202
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Table 1
Study schedule.
Group Month 0 Month 1 Month 2
Dose  1 Dose  2
PCV13 + TIV/Placebo Blood draw Blood draw Blood draw
PCV13  + TIV Placebo
Placebo + TIV/PCV13 Blood draw Blood draw Blood draw
Placebo  + TIV PCV13196 T.F. Schwarz et al. / Va
onconjugated PPV. Pneumococcal conjugate vaccines, including
CV13, have demonstrated immunogenicity and safety in older
dults [4,8,9].
PPV  and the trivalent inactivated inﬂuenza vaccine are com-
only recommended for older adults [10]. The ability to administer
oth vaccines concomitantly, when appropriate, is an important
ay to facilitate immunization. Compatibility of the nonconjugated
PV coadministered with the inﬂuenza vaccine has been demon-
trated previously [10,11].
The current study evaluates the safety and immunogenicity of
CV13 when administered concomitantly with the trivalent inac-
ivated inﬂuenza vaccine (TIV) in adults aged ≥65 years who  are
aïve to PPVs. This study was performed as part of an ongoing
rogram to develop PCV13 for use in adults. It was  carried out
efore the start of a large scale efﬁcacy study to establish the
fﬁcacy of PCV13 to prevent a ﬁrst episode of vaccine serotype-
peciﬁc pneumococcal community-acquired pneumonia, and to
stablish a protective antibody level in adults aged ≥65 years in The
etherlands [12]. In the efﬁcacy study, some participants received
CV13 and TIV concomitantly.
.  Patients and methods
This  was a parallel-group, randomized, double-blind, multicen-
er trial conducted at 39 sites (3 hospital clinics and 36 general
ractices) in Germany, The Netherlands, Belgium, and Hungary. The
rial was registered at Clinicaltrials.gov as number NCT00492557.
.1.  Participants
Participants were recruited by infectious disease specialists and
eneral practitioners. Some sites used ﬂyers and ofﬁce adver-
isements to draw attention to the study. Potential participants
eceived written information about the study (informed consent
ocument) to review. Before signing the informed consent for study
articipation, the study physician answered all study-related ques-
ions. Participants were not paid for their participation, but were
eimbursed for expenses for their travel, parking, and meals. The
tudy vaccines (PCV13 and TIV) were supplied free of charge. All
ecruitment documents and anticipated costs for reimbursement
ayments were reviewed and approved by the ethics committees
oncerned. Participants were enrolled from October 2007 to Febru-
ry 2008. The trial was conducted in accordance with the ethical
rinciples of the Declaration of Helsinki and all participants pro-
ided written informed consent before enrollment.
Healthy men  and women aged ≥65 years were eligible for
nrollment. Participants were ineligible if they had: a history of
. pneumoniae infection within the previous 5 years; were previ-
usly vaccinated with any pneumococcal vaccine, or vaccinated
ith inﬂuenza- or diphtheria-containing vaccine within 6 months
f study vaccine; had received blood products or immunoglob-
lins within the previous 6 months; had known or suspected
mmunodeﬁciency or suppression; had serious chronic illness with
ulmonary, renal, or cardiac failure; had evidence of severe cog-
itive impairment; or were residents in a nursing home or other
ong-term care facility.
.2.  Interventions
Eligible participants received either PCV13 given concomi-
antly with TIV (PCV13 + TIV) followed 1 month (day 29–43) later
y placebo (PCV13 + TIV/Placebo) or placebo given concomitantly
ith TIV (Placebo + TIV) followed 1-month (day 29–43) later by
CV13 (Placebo + TIV/PCV13). Vaccinations (0.5-mL dose) were
iven intramuscularly into the left (PCV13 or Placebo) and rightPCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated
inﬂuenza  vaccine.
(TIV) deltoid muscle. Three blood samples were taken; at baseline
and 1 month after each vaccination (Table 1).
2.3. Vaccines administered
PCV13  contains saccharides from pneumococcal serotypes 1, 3,
4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 23F individually con-
jugated to nontoxic diphtheria toxin cross-reactive material 197
(CRM197). The vaccine is formulated at pH 5.8 with 5 mM succinate
buffer, 0.85% sodium chloride and 0.02% polysorbate 80, and is for-
mulated to contain 2.2 g of each saccharide, except for 4.4 g of
6B per 0.5-mL dose. The vaccine also contains 0.125 mg  aluminum
as aluminum phosphate per 0.5-mL dose.
The placebo was formulated similarly, but without the CRM197
conjugated pneumococcal saccharides. PCV13 and placebo were
ﬁlled in identical containers, so that their appearances matched.
The  split virion, inactivated TIV (Fluarix® 2007/2008, Glaxo-
SmithKline Biological SA), contains strains of inﬂuenza viruses that
are antigenically equivalent to the annually recommended strains
of one inﬂuenza A/H1N1 virus (15 g), one A/H3N2 virus (15 g),
and one B virus (15 g) per 0.5-mL dose of vaccine.
2.4.  Study objectives
This  study was  designed to test whether the immune responses
induced by the concomitant administration of PCV13 + TIV to anti-
gens A/HIN1, A/H3N2 and B are noninferior to those induced by
TIV alone (TIV + Placebo), and that the immune responses to the
PCV13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and
23F) induced by PCV13 + TIV are noninferior to those induced by
PCV13 administered 1 month after TIV.
The safety proﬁle of PCV13 + TIV compared with that of each
agent alone was also assessed.
2.5.  Immunogenicity assessments
The  immune responses induced by PCV13 + TIV were compared
with those of TIV alone (Placebo + TIV), as measured by the stan-
dard hemagglutination inhibition (HAIs) assays for the TIV strains
(A/H1N1, A/H3N2, and B) 1 month after TIV vaccination, and with
PCV13 alone in a subset of 605 participants, as measured by a
standardized enzyme-linked immunosorbent assay for serotype-
speciﬁc immunoglobulin G (IgG) 1 month after PCV13 vaccination
[13].
For TIV antigens (A/H1N1, A/H3N2, and B), a responder was
deﬁned as a participant achieving a ≥4-fold increase in HAI
titres from prevaccination to 1 month postvaccination. A compar-
ison between the two treatment groups (PCV13 + TIV relative to
Placebo + TIV) was based on the difference in proportions of respon-
ders. Noninferiority was declared if the lower limit of the 2-sided
95% conﬁdence interval (CI) for the difference in the proportion
of responders between groups ([PCV13 + TIV] − [Placebo + TIV]) was
greater than −0.10 consistent with existing literature [14].
Serotype-speciﬁc anticapsular polysaccharide IgG geometric
mean concentrations (GMCs) were calculated for each of the 13
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neumococcal serotypes. A comparison between the two  treat-
ent groups (PCV13 + TIV relative to PCV13) was based on the ratio
f GMCs for each of the pneumococcal serotypes. Noninferiority
as declared if the lower limit of the 2-sided 95% CI for the GMC
atio ([PCV13 + TIV]:PCV13) was >0.5 (2-fold criterion) calculated
-month after PCV13 vaccination. PCV13 efﬁcacy data in the adult
opulations are not yet available. For the purpose of comparing
roups administered PCV13 with and without TIV, a 0.5 margin
as applied. This deﬁnition was considered to be reasonable on
he basis of GMC  ratios of 2- to 3-fold seen among serotypes, and
cross several of the infant PCV7 or PCV9 efﬁcacy trials [15]. These
ifferences are not manifested as differences in efﬁcacy among
he serotypes. Therefore, geometric mean immune response val-
es that are within a 2–3-fold range are unlikely to manifest as a
linically signiﬁcant change in the effectiveness of the vaccine. This
oninferiority margin was consistent with relevant publications at
he time of study design [14].
Additionally, the immune response of PCV13 + TIV was  assessed
ased on the European Medicines Agency (EMA) “Note for Guid-
nce on Harmonisation of Requirements for Inﬂuenza Vaccines”
16]. This includes the proportion of responders to A/H1N1,
/H3N2, and B based on a signiﬁcant increase in antihemag-
lutinin antibody titre >30%; geometric mean fold rise (GMFR)
2.0; and the proportion of participants achieving an HAI titre
40 is >60%.
.6.  Safety assessments
Local  reactions (redness, swelling, pain, and limitation of arm
ovement) at the PCV13 injection site and systemic events, includ-
ng fever (oral temperature ≥38 ◦C), chills, fatigue, headache,
omiting, decreased appetite, rash, and new and aggravated gen-
ralized muscle or joint pain, and the use of antipyretic and pain
edications to treat symptoms, was recorded for 14 days in an elec-
ronic diary by the participants. Other adverse events, which were
ollected by the investigator in response to direct questioning of the
ubject on his/her health since the last visit, were documented on
he case report form at each visit throughout the study; the investi-
ator assessed each adverse event for severity, for serious criteria,
nd causality.
.7. Sample size
Sample  size estimation was based on the proportion of respon-
ers (achieving at least a 4-fold increase in HAI titre) in each group
or TIV comparisons, and the GMCs in each group for PCV13 com-
arisons. Sample sizes were calculated using nQuery Advisor® 6.0
Statistical Solutions, Ltd., Cork, Ireland). This study was  powered
o show noninferiority of PCV13 + TIV relative to Placebo + TIV and
CV13 alone.
For  TIV comparisons, sample size calculations assumed power
f at least 80%; a noninferiority criterion of −0.10 for the differ-
nce in proportions of responders; no difference in true responses
etween the groups ([PCV13 + TIV]−[Placebo + TIV alone]); a 2-
ided, type-I error rate of 0.05; and a dropout rate of ≤7%. With
hese assumptions, 511 evaluable participants per group were
eeded for TIV comparisons. A total of 1160 participants were
andomly assigned to ensure 1022 evaluable participants for TIV
omparisons.
For IgG comparisons, sample size calculations assumed
ower of approximately 90%; 2-fold noninferiority criterion for
MCs; no difference in true responses between the groups
[PCV13 + TIV] − [PCV13 alone]); a 2-sided, type-I error of 0.05;
nd a dropout rate of ≤7%. With these assumptions, 281 evalu-
ble participants per group were needed for pneumococcal
omparisons.29 (2011) 5195– 5202 5197
2.8. Randomization
Eligible participants were randomly assigned in a 1:1 ratio
to receive PCV13 + TIV/Placebo or Placebo + TIV/PCV13 through
the sponsor’s internet-based enrollment system. This system was
accessed through the internet or an interactive voice-response sys-
tem by authorized site staff. The randomization schedule used a
randomized block design in which treatment sequences were ran-
domly ordered within each block. All participants, study staff, and
those assessing outcomes were blinded to the group assignment.
The  selection for inclusion in the IgG subset analysis occurred
after all participants were enrolled. Participants were randomly
ordered within treatment groups and assigned a rank (1, 2,
3, etc.), then chosen in rank order, which facilitated replace-
ment when no sera were available; the next participant in
the sequence from the same treatment group was used as a
replacement.
2.9. Statistical analysis
The  statistical analyses were performed by the sponsor.
For the 3 inﬂuenza virus subtypes contained in TIV, exact, 2-
sided 95% CIs based on the procedure of Chan and Zhang [17]
were computed on the difference in proportions of responders
([PCV13 + TIV] − [Placebo + TIV]).
For the comparison of PCV13 + TIV to PCV13, IgG concentra-
tions for each vaccine group and serotype were logarithmically
transformed for analysis, and GMC  was  computed. Corresponding
2-sided 95% CIs for the GMCs were constructed by back transfor-
mation of the CI for the mean of logarithmically transformed assay
results, which were computed using the Student’s t distribution.
Noninferiority was  evaluated using the ratio of postvaccination
GMCs (PCV13 + TIV:PCV13) and corresponding 2-sided 95% CIs, and
was declared if the lower limit of the 2-sided 95% CI for the GMC
ratio was  >0.5. For the GMC  ratio, the CI was computed by back
transforming the CI for the mean difference of the measures on the
natural log scale which used the Student’s t distribution.
The fold rises in antibody concentrations from before vaccina-
tion to 1 month after vaccination were summarized by geometric
means and CIs, and were computed using the logarithmically trans-
formed assay results.
Safety  comparisons between groups were based on the 95% CI
using Chan and Zhang [17] methodology, with a difference noted
between the 2 groups if the 95% CI for the difference excluded zero.
3. Results
3.1. Baseline characteristics and participant disposition
A total of 1190 participants were enrolled. There were 29 screen
failures and 1 participant with no signed informed consent. A
total of 1160 participants were randomly assigned in a 1:1 ratio
to the PCV13 + TIV/Placebo group (n = 580) or Placebo + TIV/PCV13
group (n = 580) (Fig. 1). The evaluable immunogenicity population
included 1096 participants (PCV13 + TIV/Placebo group n = 549 and
Placebo + TIV/PCV13 group n = 547), each of whom adhered to the
protocol requirements, had valid and determinate assay results,
and had no other major protocol violations. The all-available
immunogenicity population included all participants who  had ≥1
valid and determinate assay result. Demographics for the evaluable
immunogenicity population are presented in Table 2. IgG analysis
was performed in a subset of 605 participants.
The safety population (n = 1151) included any participant who
received at least 1 dose of the study vaccine (PCV13 + TIV/Placebo
group n = 576 and Placebo + TIV/PCV13 group n = 575).
5198 T.F. Schwarz et al. / Vaccine 29 (2011) 5195– 5202
29 Screen failures 
1 Participant did not consent 
Randomized 
N=1160 
Placebo + TIV/PCV13 
(n=580) 
1190 Participants enrolled   
PCV13 + TIV/placebo 
(n=580) 
23 Withdrawals 
 11 participant requests   
 8 protocol violations  
 2 other   
 1 death 
 1 loss to follow-u p 
556 Participants completed  557 Participa nts complete d 
33 Excluded from evaluable immunogenicity 
population 
Some participants for more than 1 reason 
 10 with  no as say results for any antigen 
 1 blood draw before informed consen t  
 13 did not receive all PCV13/placebo  
vaccines 
 4 forced rando mizationsa 
 3 not eligible for the studyb  
 3 received prohibited vaccines   
 2 blood draws <28 days  after dose 1   
 1 received  vaccine  other t han  
randomized   
 1 aged <65 years on the day of first dose  
547 Participants in evaluable immunog enicity 
population 
549 Participants in evaluable immunogenicity 
population  
24 Withdrawals 
 12 participant requests  
 7 protocol violations   
 2 other   
 1 death  
 1 adverse event  
 1 failed to return   
31 Excluded from evaluable 
immunogenicity population   
Some participants for more than 1 reason 
 10 with no as say results for any antigen   
 1 blood draw before inf orm ed consent   
 11 did not receive all PCV13 /placebo 
vaccines  
 3 forced random izationsa 
 2 not eligible for the stud yb  
 1 received prohibited vaccines   
 1 blood draw <28 days after dose 1   
 2 received  vaccine other t han 
randomized  
 2 received previous pneumococcal 
vaccination  
 1 participant unbli nded   
 1 blood draw >57 days after dose 1   
Fig. 1. Participant disposition.
aForced randomization occurred when a participant received study vaccine from the available study vaccine supply without being randomized. The vaccine recipient is
then  assigned a randomization number for this treatment group. bParticipants had known or suspected immunodeﬁciency or suppression. PCV13, 13-valent pneumococcal
conjugate vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
Table  2
Demographic characteristics for the evaluable immunogenicity population.
PCV13 + TIV/Placebo Placebo + TIV/PCV13 Total
(n = 549) (n = 547) (N = 1096)
Sex, n (%)
Female 276 (50.3) 274 (50.1) 550 (50.2)
Male  273 (49.7) 273 (49.9) 546 (49.8)
Race,  n (%)
White  543 (98.9) 543 (99.3) 1086 (99.1)
Asian  3 (0.5) 2 (0.4) 5 (0.5)
Other  2 (0.4) 1 (0.2) 3 (0.3)
Black  or African-American 1 (0.2) 1 (0.2) 2 (0.2)
Mean  age at vaccination, years ± SD 72.0  ± 5.5 72.0 ± 5.4 72.0 ± 5.4
PCV13, 13-valent pneumococcal conjugate vaccine; SD, standard deviation; TIV, trivalent inactivated inﬂuenza vaccine.
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emographic characteristics in the safety population were
imilar to those in the evaluable immunogenicity population.
Participants were followed up for approximately 1 month
29–43 days) after each vaccination.
.2. Immunogenicity
.2.1. Response to TIV
The  proportions of responders (participants achieving a ≥4-
old increase in HAI titre for each TIV subtype) were similar after
CV13 + TIV compared with Placebo + TIV for A/H1N1 (80.3% and
8.6%, respectively), A/H3N2 (58.0% and 62.6%, respectively), and B
52.2% and 54.0%, respectively). Noninferiority (lower limit of the
5% CI greater than −10%) was met  for A/H1N1 and B. For A/H3N2,
he difference in the proportions of responders was −4.6%, with
 lower limit of the 95% CI of −10.4% (Table 3). The proportion of
esponders in the PCV13 + TIV group for A/H1N1 (80.3%), A/H3N2
58.0%), and B (52.2%) exceeded the EMA  guidance value of >30%
Table 3) [16].
The  HAI geometric mean titres (GMTs) were similar in the 2
roups (PCV13 + TIV compared with Placebo + TIV) at baseline and
ose substantially after vaccination. Of note, baseline HAI GMTs for
/H3N2 in both groups was higher than those for A/H1N1 and B in
oth groups (Table 4). The GMFR in the PCV13 + TIV group was ≥4.1
nd exceeded the EMA  guidance value of >2.0 [16].
The proportion of participants achieving HAI titres ≥40 for
/H1N1, A/H3N2, and B in the PCV13 + TIV group exceeded the EMA
uidance value of >60% (Table 5) [16].
.2.2. Response to PCV13
Baseline  antibody GMC  for pneumococcal serotypes ranged
rom 0.21 g/mL (serotype 4) to 2.67 g/mL (serotype 19A) in
he PCV13 + TIV group, and 0.19 g/mL (serotype 4) to 2.77 g/mL
serotype 19A) in the Placebo + TIV group (data not shown). One
onth after administration of PCV13 in each group, the overall IgG
MCs were lower in the PCV13 + TIV group relative to the PCV13
roup (administered 1 month after Placebo + TIV). The noninferi-
rity criterion for IgG GMC  ratios was met  for all serotypes except
9F, for which the lower limit of the 95% CI was  0.49, just below
he predetermined lower limit of >0.5 (2-fold criterion) (Table 6).
.3. Safety
Local reactions at the pneumococcal injection site were similar
fter PCV13 + TIV relative to after PCV13 (administered 1 month
fter Placebo + TIV) and were 46.9% and 46.6%, respectively; the
ajority was mild (Table 7).
Systemic events were reported more frequently after
CV13 + TIV relative to Placebo + TIV (60.1% vs. 50.5%), with
tatistical evidence of a percentage difference between the two
roups for any systemic event (95% CI 3.4; 15.7), chills (95% CI 0.5;
.9), rash (95% CI 0.4; 6.6), and new muscle pain (95% CI 4.9; 15.6)
Table 8).
Systemic events were reported more frequently after
CV13 + TIV relative to PCV13 alone (60.1% vs. 48.5%), with
tatistical evidence of a percentage difference for any systemic
vent (95% CI 5.4; 17.8), fatigue (95% CI 2.8; 14.9), headache (95%
I 2.1; 13.8), chills (95% CI 0.4; 9.0), decreased appetite (95% CI 1.0;
0.2), new joint pain (95% CI 0.1; 9.2), and any aggravated joint
ain (95% CI 2.7; 11.4) (Table 8).
Overall, fever rates were low and fever was  mild or moderate
n severity. There were no vaccine-related serious adverse events
SAEs) during the study. One SAE (angina pectoris with ST-segment
levation on day 10) after placebo in the PCV13 + TIV/Placebo
roup caused withdrawal of a participant. Two  SAEs resulted
n death; 1 case of cardiac failure on day 3 after placebo29 (2011) 5195– 5202 5199
(PCV13 + TIV/Placebo) and 1 case of gastrointestinal hemorrhage
with perforated duodenal ulcer and peritonitis on day 29 after
PCV13 (Placebo + TIV/PCV13).
4.  Discussion
In this study, which included predominantly white adults aged
≥65 years who  were naïve to PPV, the immunogenicity and safety
responses to the three viral subtypes in TIV (A/H1N1, A/H3N2, and
B) and each of the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, and 23F) in PCV13 after concomitant administration
of PCV13 and TIV were directly compared with TIV (and placebo)
or PCV13 administered after TIV.
A clinically meaningful, empirically determined level of anti-
bodies against pneumococcal or inﬂuenza antigens that is
protective against disease in adults is lacking. A correlation
between antibody levels and protection against invasive pneu-
mococcal disease was demonstrated previously in children [18].
Therefore, as in most vaccine trials, the endpoints of the present
trial were based on a comparison of the relative changes in immune
response between administration of the vaccines separately or
together [19–21]. For TIV antigens, the immune response corre-
lates of protection are considered to be acceptable levels of serum
antibody to the individual vaccine hemagglutinins as measured
by HAI and described in “Note for Guidance on Harmonisation of
Requirements for Inﬂuenza Vaccines” [16].
The analysis of TIV (A/H1N1, A/H3N2, and B) immune responses,
based on the proportion of responders achieving at least a 4-fold
rise in HAI titre, showed that noninferiority of PCV13 + TIV relative
to TIV was met  for A/H1N1 and B; for A/H3N2, the difference in
proportions of responders was  −4.6%, with a lower limit of the 95%
CI of −10.4%, which was slightly lower than the more than −10.0%
predeﬁned margin of noninferiority. However, it was noted that
in contrast with the other two virus subtypes, the mean predose-
1 titres for A/H3N2 were quite high, perhaps reﬂecting pressure
from A/H3N2 epidemics that occurred in the years prior to the
study. In the regions where the study was conducted, H3N2 pre-
dominated over H1N1 and B in the 2006–2007 season [22]. Higher
pre-immunization titres may  limit the likelihood of demonstrat-
ing 4-fold responses, and the lower frequency of response would
be expected to impact the ability to demonstrate noninferiority.
Notably, H3N2 responder rates at an HAI titre ≥40 were compara-
ble in the PCV13 + TIV and Placebo + TIV groups, indicating a high
likelihood of protection against H3N2. In fact, all criteria proposed
in the EMA  “Note for Guidance on Harmonisation of Requirements
for Inﬂuenza Vaccines” [16] were exceeded for all three TIV anti-
gens (H1N1, H3N2, and B) when TIV was administered with PCV13.
The data support the conclusion that TIV is sufﬁciently immuno-
genic when given concomitantly with PCV13, and that protection
against inﬂuenza is likely to be clinically indistinguishable from
that provided by TIV alone.
The  IgG GMCs of the 13 serotypes after PCV13 + TIV were uni-
formly lower compared with the responses after PCV13 alone.
However, the lower responses were still within the 2-fold GMC  cri-
terion for noninferiority for all pneumococcal serotypes, with the
exception of 19F, which was  just below the noninferiority margin.
The lower immune response observed by concomitant adminis-
tration of these vaccine antigens is not easily understood. Such
interactions are thought to be caused by complex, multi-factorial
interactions, including antigen competition, and the effects of other
vaccine components on the immune response [23]. A possible
mechanism could be that vaccine antigens interfere with the MHC
class I and II antigen processing and presentation pathways, leading
to a uniformly reduced response to PCV13 serotypes [24]. Further
research is required to better understand this phenomenon.
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Table  3
Proportion of participants with a ≥4-fold increase in titer after dose 1 for TIV antigens—evaluable immunogenicity population.
PCV13 + TIV/Placebo Placebo + TIV/PCV13 Difference
n/N % (95% CI) n/N % (95% CI) % (95% CI)
A/H1N1 440/548 80.3 (76.7; 83.5) 429/546 78.6 (74.9; 81.9) 1.7 (−3.1; 6.5)
A/H3N2  316/545 58.0 (53.7; 62.2) 341/545 62.6 (58.4; 66.6) −4.6 (−10.4; 1.3)
B  286/548 52.2 (47.9; 56.4) 295/546 54.0 (49.7; 58.3) −1.8 (−7.8; 4.1)
CI, conﬁdence interval; n, number of participants with an antibody titer that met the prespeciﬁed criteria; N, number of participants with a determinate antibody titer for
the  given concomitant vaccine antigen; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
Table  4
Standard hemagglutination inhibition assay GMTs before and after dose 1 and GMFR after dose 1—evaluable immunogenicity population.
TIV antigen vaccine received Predose 1 Postdose 1 Postdose 1/predose 1
n GMT  (95% CI) n GMT (95% CI) n GMFR (95% CI)
A/H1N1
PCV13 + TIV 548 21.6 (19.9; 23.6) 548 195.5 (176.6; 216.4) 548 9.0 (8.1; 10.1)
Placebo  + TIV 547 22.5 (20.5; 24.6) 546 191.9 (173.4; 212.5) 546 8.5 (7.7; 9.5)
A/H3N2
PCV13  + TIV 545 62.9 (55.8; 70.9) 545 327.4 (293.5; 365.2) 545 5.2 (4.6; 5.9)
Placebo  + TIV 546 65.3 (57.5; 74.1) 545 413.2  (370.5; 460.8) 545 6.3 (5.5; 7.2)
B
PCV13  + TIV 548 22.3 (20.4; 24.3) 548 90.4 (81.6; 100.2) 548 4.1 (3.7; 4.5)
Placebo  + TIV 547 22.5 (20.6; 24.6) 546 88.5 (79.8; 98.1) 546 3.9 (3.6; 4.3)
GMFR, geometric mean fold rise; GMT, geometric mean titer; n, number of participants with valid and determinate assay results at the given visit; PCV13, 13-valent
pneumococcal conjugate vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
Table 5
Proportion of participants achieving hemagglutination inhibition assay titer ≥40 after dose 1—evaluable immunogenicity population.
TIV antigen PCV13 + TIV/Placebo Placebo + TIV/PCV13
n/N % (95% CI) n/N % (95% CI)
A/H1N1 515/548 94.0 (91.6; 95.8) 514/546 94.1 (91.8; 96.0)
A/H3N2  526/545 96.5 (94.6; 97.9) 531/545 97.4 (95.7; 98.6)
B  449/548 81.9 (78.5; 85.1) 444/546 81.3 (77.8; 84.5)
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omparison of pneumococcal IgG GMC  1 month after dose 1 for PCV13 + TIV/Placebo and 1 
Postdose 1a
PCV13  + TIV/Placebo 
Serotype nb GMC, g/mL 
1 276 2.52 
3  272 1.08 
4  279 2.15 
5 253  4.74 
6A  272 4.61 
6B  278 6.24 
7F  273 7.63 
9V  250 4.97 
14 272  8.95 
18C  247 8.88 
19A  266 11.93 
19F  277 4.78 
23F  277 5.82 
a Comparisons were made 1 month (i.e. 29–43 days) after participants received PCV13
nd 1 month (29–43 days) after dose 2 in the Placebo + TIV/PCV13 group.
b Number of participants with valid and determinate antibody concentrations for each
MC,  geometric mean concentration; IgG, immunoglobulin G; n, number of participan
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Although immune responses to vaccine antigens were observed
after receipt of both vaccines, the lack of knowledge about the
threshold level of antibodies needed to protect against pneumo-
coccal disease in adults is a limitation of the study. The results
from the efﬁcacy study of PCV13 being conducted in adults aged
≥65 years in The Netherlands are awaited to help establish an
month after dose 2 for Placebo + TIV/PCV13—evaluable immunogenicity population.
Postdose 2a Vaccine comparison
Placebo + TIV/PCV13
nb GMC, g/mL Ratio (95% CI)
270 3.20 0.79 (0.60; 1.04)
273 1.15 0.94 (0.78; 1.13)
278 3.24 0.66 (0.51; 0.87)
255 6.90 0.69 (0.55; 0.86)
264 6.10 0.76 (0.61; 0.94)
264 6.43 0.97 (0.75; 1.25)
253 9.04 0.84 (0.67; 1.07)
247 6.21 0.80 (0.63; 1.02)
277 12.44 0.72 (0.53; 0.97)
261 11.07 0.80 (0.64; 1.01)
255 17.10 0.70 (0.56; 0.87)
276 7.39 0.65 (0.49; 0.85)
265 6.11 0.95 (0.71; 1.27)
; this occurred 1 month (29–43 days) after dose 1 in the PCV13 + TIV/Placebo group
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Table  7
Percentage of participants with local reactions at the PCV13 injection site within 14 days after vaccination—safety population.
Reaction PCV13 + TIV PCV13 alone Difference (%)
% (n/N) % (n/N) (95% CIa)
Any 46.9  (229/488) 46.6 (219/470) 0.3 (−6.0; 6.7)
Redness 16.6 (73/440) 12.3 (53/432) 4.3 (−0.4; 9.0)
Swelling  13.8 (61/441) 10.2 (44/431) 3.6 (−0.7; 8.0)
Pain 40.0  (192/480) 43.4 (204/470) −3.4 (−9.7; 3.0)
Limitation of arm movement 13.9 (62/445) 14.8 (64/432) −0.9 (−5.6; 3.8)
a Exact 2-sided CI for the difference in proportions, (PCV13 + TIV) − (Placebo + TIV/PCV13), expressed as a percentage.
CI,  conﬁdence interval; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
Table 8
Percentage of participants with systemic events within 14 days of vaccination—Safety population.
Systemic events PCV13 + TIV Placebo + TIV Difference % (95 CI)
PCV13  + TIV vs.
Placebo + TIV
PCV13  Difference % (95 CI)
PCV13  + TIV vs. PCV13
%  (n/N) % (n/N) % (n/N)
Any fever ≥38 ◦C 4.2 (18/431) 3.2 (14/433) 0.9 (−1.7; 3.6) 3.6 (15/422) 0.6 (−2.1; 3.3)
Fever  ≥38 ◦C but <38.5 ◦C 3.0 (13/430) 1.9 (8/431) 1.2 (−1.0; 3.4) 3.1 (13/422) −0.1 (−2.5; 2.4)
Fever  ≥38.5 ◦C but <39 ◦C 1.4 (6/425) 1.2 (5/430) 0.2 (−1.5; 2.0) 1.0 (4/420) 0.5 (−1.2; 2.2)
Fever  ≥39 ◦C but ≤40 ◦C 0 (0/423) 0.2 (1/428) −0.2 (−1.3; 0.6) 0 (0/419) 0.0 (−0.9; 0.9)
Fever  >40 ◦C 0 (0/423) 0 (0/428) 0 (−0.9; 0.9) 0 (0/419) 0 (−0.9; 0.9)
Fatigue 37.4  (178/476) 31.9 (154/483) 5.5 (−0.5; 11.5) 28.5 (130/456) 8.9 (2.8; 14.9)
Headache  32.6 (154/472) 29.7 (139/468) 2.9 (−3.0; 8.9) 24.7 (111/449) 7.9 (2.1; 13.8)
Chills  13.8 (61/443) 9.1 (40/440) 4.7 (0.5; 8.9) 9.1 (39/429) 4.7 (0.4; 9.0)
Rash 6.9  (30/433) 3.4 (15/436) 3.5 (0.4; 6.6) 6.8 (29/427) 0.1 (−3.3; 3.6)
Vomiting  3.0 (13/432) 3.4 (15/437) −0.4 (−2.9; 2.0) 1.7 (7/424) 1.4 (−0.7; 3.6)
Decreased  appetite 16.9 (76/450) 14.6 (66/452) 2.3 (−2.5; 7.1) 11.3 (49/434) 5.6 (1.0; 10.2)
New  muscle pain 26.9 (126/468) 16.7 (76/456) 10.3 (4.9; 15.6) 23.4 (105/448) 3.5 (−2.2; 9.1)
Any  aggravated muscle pain 18.7 (85/454) 14.0 (63/449) 4.7 (−0.2; 9.6) 15.0 (66/439) 3.7 (−1.2; 8.7)
New  joint pain 16.2 (73/452) 13.1 (59/451) 3.1 (−1.6; 7.7) 11.5 (50/435) 4.7 (0.1; 9.2)
Any  aggravated joint pain 15.7 (71/452) 13.0 (58/447) 2.7 (−1.9; 7.4) 8.6 (37/428) 7.1 (2.7; 11.4)
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I, conﬁdence interval; PCV13, 13-valent pneumococcal conjugate vaccine; TIV, triv
ffective antibody level against pneumococcal disease in adults
12].
Overall, the concomitant administration of PCV13 and TIV was
emonstrated to be immunogenic and safe. If PCV13 is determined
o add value in a comprehensive immunization strategy against
neumococcal disease, the ability to coadminister PCV13 and TIV
ould facilitate the immunization of older adults.
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